|
A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients with Metastatic Esophageal Cancer Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients with Metastatic Esophageal Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients with Metastatic Esophageal Cancer Clinical research trials and A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients with Metastatic Esophageal Cancer health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients with Metastatic Esophageal Cancer. A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients with Metastatic Esophageal Cancer Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients with Metastatic Esophageal Cancer clinical trial. Test subjects typically receive the most expert healthcare available for their A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients with Metastatic Esophageal Cancer condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients with Metastatic Esophageal Cancer  A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients with Metastatic Esophageal Cancer
A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients with Metastatic Esophageal Cancer
For Condition: Esophageal Neoplasm
Status: Recruiting
Sponsor(s): Edelman, Martin, M.D. , Bristol-Myers Squibb
Synopsis: This study is for patients with esophageal cancer that has spread to other areas. The purpose of this study is to: 1. Determine how well a combination of taxol, UFT, and leucovorin work in these patients, 2. Determine the survival of patients with metastatic esophageal carcinoma treated with this combination of drugs. 3. Identify the side effects of this drug combination.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/79 Years
Genders: Both
Protocol Entry Criteria: INCLUSION - Histologic proof of esophageal cancer - No more than one prior non-taxane chemotherapy regimen for either treatment of localized disease or metastatic disease AND they may not have received a regimen containing low dose continuous infusion of 5-FU (i.e. >5 days of infusion/cycle), capecitabine or UFT - No prior therapy with UFT+/-leucovorin, a taxane, capecitabine, low dose continuous infusion of 5-FU or ethynyl uracil. - Radiographic or physical examination documentation of metastatic disease - No major surgery within the 2 weeks preceding the start of treatment and fully recovered from any complications of surgery - No radiation within 2 weeks of beginning chemotherapy. - No chemotherapy within 4 weeks of beginning treatment. - Patients must wait at least 6 weeks after receiving BCNU or Mitomycin-C. - Minimum life expectancy of 3 months - Informed consent given - Laboratory values within limits set by study. EXCLUSION - More than one prior chemotherapy regimen for metastatic disease - Current serious medical or psychiatric illness that would prevent informed consent or intensive treatment - >grade 1 peripheral sensory or motor neuropathy - Pregnant - Patient is taking the drug Sorivudine
Total Enrollment:
Location and Contact Information:
University of Maryland Cancer Center *Recruiting*
Baltimore, Maryland, 21201
United States
Recruiting Ruth Smith 410-328-9166
Additional Information:
Study ID Numbers: BMS-200604; UMCC 0110g
Study Start Date:
Record last reviewed: May 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00037089
Other Esophageal Neoplasm Studies:
1. Vaccine Therapy and Detection of Immunologic Responses with Human Papillomavirus 16 E6 and E7 Peptides in Patients with Metastatic or Locally Advanced Cervical Cancer and Other Cancers Carrying the HPV
2. The Effects of Upper Airway and Digestive Tract Tumors on the Immune System
3. A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients with Metastatic Esophageal Cancer
4. Familial Aggregation of Barrett's Esophagus
Related Studies:
Other Esophageal Neoplasm Clinical Trials
Other Maryland Clinical Trials
Other Baltimore Clinical Trials
A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients with Metastatic Esophageal Cancer
|
|
|
|
|
|
|
|
